Nutrition 21
This article was originally published in The Tan Sheet
Executive Summary
Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...
You may also be interested in...
Nutrition 21 Diachrome, Zeramax Sales To Be Backed By Research Initiatives
Nutrition 21 plans to support the broad launch of its Diachrome chromium picolinate/biotin blend with a relatively large-scale clinical study, according to President and CEO Gail Montgomery
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.